Showing 1–8 of 8 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Álvaro H Borges, Marisa Russell, Dereck Tait, Thomas J Scriba, Elisa Nemes, et al.
**BACKGROUND:** People with tuberculosis who complete treatment remain at risk of recurrent disease. The vaccine H56:IC31 has been shown to be safe and immunogenic in phase 1 and 2 studies, but whether it can reduce the risk of tuberculosis recurrence is unknown. **METHODS:** In…
Chuang YM, Dutta NK, Gordy JT, Campodónico VL, Pinn ML, et al.
The lengthy and complicated current regimen required to treat drug-susceptible tuberculosis (TB) reflects the ability of Mycobacterium tuberculosis (Mtb) to persist in host tissues. The stringent response pathway, governed by the dual (p)ppGpp synthetase/hydrolase, Rel Mtb , is a…
Tait D, Diacon A, Borges ÁH, van Brakel E, Hokey D, et al.
Background H56:IC31 is a candidate vaccine against tuberculosis (TB) with the potential to reduce TB recurrence rate. It is thus important for future clinical trials to demonstrate safety and immunogenicity of H56:IC31 in individuals treated for TB. Methods Twenty-two adults conf…
Shurygina AS, Zabolotnykh NV, Vinogradova TI, Vitovskaya ML, Dogonadze MZ, et al.
…pment of innovative treatment approaches. Immunotherapeutic vaccines have the potential to effectively regulate the anti-TB immune response and enhance the efficacy of anti-TB treatment. In the present study, we aimed to evaluate the potency of the mucosal vector vaccine TB/FLU-0…
Sarah Schmidiger, Damien Portevin
…ing cause of death from a single-infectious agent. Improved vaccines, diagnostics and treatment regimens for drug-susceptible and drug-resistant cases are paramount to attain the goals of the WHO's End TB Strategy. Our knowledge gap in protective immunity in TB impedes the develo…
Katherine C Horton, Alvaro Schwalb, Martin J Harker, Lara Goscé, Elena Venero-Garcia, et al.
**BACKGROUND:** While a range of interventions exist for tuberculosis prevention, screening, diagnosis, and treatment, their potential population impact and cost-effectiveness are seldom directly compared, or evaluated between settings with different background TB epidemiology an…
Heunis C, Chikobvu P, Muteba M, Kigozi-Male G, Engelbrecht M, et al.
Background In an attempt to discern lessons to improve future pandemic responses, this study measured the effects of the COVID-19 pandemic on essential public health services (EPHSs) related to primary health care (PHC) and outpatient department (OPD) utilisation, antiretroviral …
Kerkhoff AD, Zucker J, Havlir DV
Several novel antituberculosis agents, including long-acting injectable agents in mouse models, have shown promise in preclinical and early clinical studies. This encouraging news is offset by the failures of a tuberculosis (TB) vaccine to prevent disease recurrence and a 3-month…